LIVIVO - Search results -

Search results

Result 1 - 10 of total 29

Search options

Article ; Online: Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases.

Liu, Chunxiao / Zhang, Xiang / Mao, Liping / Qian, Jiejing / Xiao, Feng / Ye, Xiujin / Wei, Juying / Ye, Xingnong / Jin, Jie / Yu, Wenjuan

Leukemia & lymphoma

2023 Volume 64, Issue 6, Page(s) 1208–1211

MeSH term(s)	Humans ; Philadelphia Chromosome ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Recurrence ; B-Lymphocytes ; Acute Disease
Chemical Substances	olverembatinib (KV1M7Q3CBP)
Language	English
Publishing date	2023-04-17
Publishing country	United States
Document type	Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	1042374-6
ISSN	1029-2403 ; 1042-8194
ISSN (online)	1029-2403
ISSN	1042-8194
DOI	10.1080/10428194.2023.2197534
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2997: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Co-existence of myeloproliferative neoplasias and β-thalassemia with IVS-2-654 mutation-a case report.

Wu, Cai / Zhang, Xuewu / Ye, Xingnong / Chen, Dan / Jin, Jie / Huang, Jian

Translational cancer research

2022 Volume 9, Issue 3, Page(s) 2069–2073

Abstract: Thalassemia and myeloproliferative neoplasias (MPNs) are recognized as two separate diseases. Thalassemia is a hemolytic disease caused by abnormal goblin genes, which results in the deficiency of globin chains. MPNs are clonal hematopoietic stem cell ... ...

Abstract	Thalassemia and myeloproliferative neoplasias (MPNs) are recognized as two separate diseases. Thalassemia is a hemolytic disease caused by abnormal goblin genes, which results in the deficiency of globin chains. MPNs are clonal hematopoietic stem cell diseases characterized by the proliferation of multiple myeloid lineages. The coexistence of thalassemia and myeloproliferative neoplasia are rarely reported. We herein describe a case of a 24-year-old woman, previously diagnosed as β-thalassemia, with a lifelong history of thrombocytosis. She was subsequently diagnosed as low-risk essential thrombocythemia (ET), one of the MPNs. The patient was treated with folic acid supplementation and Iron-chelating therapy, without aspirin or cytoreductive therapy. Up to date, no thrombotic events or disease-related bleeding are happening to the patient, who remains in good health. Furthermore, we found three novel genes mutations EP300, CUX1, and FGFR3 after next-generation sequencing. We presume that the mutations of these genes in β-thalassemia might have an impact on the happening of ET and therefore need further investigations.
Language	English
Publishing date	2022-01-15
Publishing country	China
Document type	Case Reports
ZDB-ID	2901601-0
ISSN	2219-6803 ; 2218-676X
ISSN (online)	2219-6803
ISSN	2218-676X
DOI	10.21037/tcr.2020.01.48
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article: BCOR

Jin, Jingxia / Luo, Shuna / Ye, XingNong / Huang, Jian

OncoTargets and therapy

2019 Volume 12, Page(s) 7123–7127

Abstract: Acute myeloid leukemia (AML) originates from the abnormal clonal proliferation of myeloblasts. Immunoglobulin is secreted by B cells. AML with monoclonal antibody often indicates a poor prognosis. Here we report a case ... ...

Abstract	Acute myeloid leukemia (AML) originates from the abnormal clonal proliferation of myeloblasts. Immunoglobulin is secreted by B cells. AML with monoclonal antibody often indicates a poor prognosis. Here we report a case of
Language	English
Publishing date	2019-09-02
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	2495130-4
ISSN	1178-6930
ISSN	1178-6930
DOI	10.2147/OTT.S218805
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study.

You, Liangshun / Liu, Yi / Mai, Wenyuan / Xie, Wanzhuo / Zhou, De / Mao, Liping / Chen, Lili / Zhou, Xinping / Ma, Liya / Zheng, Xiaolong / Wei, Juying / Lou, Yinjun / Ye, Xingnong / Tong, Hongyan / Jin, Jie / Meng, Haitao

European journal of cancer (Oxford, England : 1990)

2024 Volume 202, Page(s) 113979

Abstract: Background: The outcome of relapsed/refractory (R/R) acute myeloid leukemia (AML) remains extremely poor. Venetoclax (VEN)-based regimens have shown promise in treating R/R AML.: Objective: This phase 2 study aimed to systematically evaluate the ... ...

Abstract	Background: The outcome of relapsed/refractory (R/R) acute myeloid leukemia (AML) remains extremely poor. Venetoclax (VEN)-based regimens have shown promise in treating R/R AML. Objective: This phase 2 study aimed to systematically evaluate the efficacy and safety of the VAA regimen (VEN plus Cytarabine and Azacitidine) in R/R AML patients. Methods: Thirty R/R AML patients were enrolled. The study adopted a stepwise ramp-up of VEN dosing, starting with 100 mg on day 1, escalating to 200 mg on day 2, and reaching 400 mg from day 3 to day 9. Cytarabine (10 mg/m Results: The CRc rate was 63.3% (19/30), with CR in 36.7% of patients and CRi in 26.7%. Notably, 14 (73.7%) of 19 patients achieving CRc showed undetectable measurable residual disease by flow cytometry. With a median follow-up of 10.7 months, the median OS had not been reached, and the median DOR was 18.3 months. The most common grade 3-4 adverse events (AEs) were neutropenia (100%), anemia (96.7%), thrombocytopenia (90.0%), and leukopenia (90.0%). Infections, with pneumonia being the most prevalent (43.3%), were observed, including one fatal case of Pseudomonas aeruginosa septicemia. There were no treatment-related deaths. Conclusion: The VAA regimen is an effective and safe option for patients with R/R AML, demonstrating a high CRc rate and manageable safety profile.
MeSH term(s)	Humans ; Cytarabine/adverse effects ; Azacitidine ; Leukemia, Myeloid, Acute/drug therapy ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Pathologic Complete Response ; Leukopenia/chemically induced ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Sulfonamides
Chemical Substances	Cytarabine (04079A1RDZ) ; Azacitidine (M801H13NRU) ; venetoclax (N54AIC43PW) ; Bridged Bicyclo Compounds, Heterocyclic ; Sulfonamides
Language	English
Publishing date	2024-03-01
Publishing country	England
Document type	Clinical Trial, Phase II ; Journal Article
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2024.113979
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Venetoclax plus '2 + 5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis.

Wang, Huafeng / Yao, Yiyi / Mao, Liping / Lou, Yinjun / Ren, Yanling / Ye, Xingnong / Yang, Min / Ma, Liya / Zhang, Yi / Zhou, Yile / Wu, Jiaying / Huang, Xin / Wang, Yungui / Xu, Huan / Tong, Hongyan / Zhu, Hong-Hu / Jin, Jie

British journal of haematology

2023 Volume 201, Issue 3, Page(s) 568–572

MeSH term(s)	Humans ; Aged ; Daunorubicin/therapeutic use ; Cytarabine/therapeutic use ; Retrospective Studies ; Leukemia, Myeloid, Acute/etiology ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Remission Induction
Chemical Substances	Daunorubicin (ZS7284E0ZP) ; Cytarabine (04079A1RDZ) ; venetoclax (N54AIC43PW) ; Bridged Bicyclo Compounds, Heterocyclic
Language	English
Publishing date	2023-03-02
Publishing country	England
Document type	Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	80077-6
ISSN	1365-2141 ; 0007-1048
ISSN (online)	1365-2141
ISSN	0007-1048
DOI	10.1111/bjh.18709
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.182: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: a propensity score matching analysis.

Liu, Chunxiao / Zhang, Xuewu / Zhu, Yanan / Wei, Juying / Ye, Xingnong / Yang, Chunmei / Tong, Hongyan / Mai, Wenyuan / Yang, Min / Qian, Jiejing / Mao, Liping / Meng, Haitao / Jin, Jie / Yu, Wenjuan

Annals of hematology

2023 Volume 102, Issue 9, Page(s) 2387–2395

Abstract: B-cell lymphoma is the most prevalent type of non-Hodgkin lymphoma, for which the standard treatment regimen includes rituximab combined with CHOP. However, some patients may develop interstitial pneumonitis (IP), which can be caused by various factors; ... ...

Abstract	B-cell lymphoma is the most prevalent type of non-Hodgkin lymphoma, for which the standard treatment regimen includes rituximab combined with CHOP. However, some patients may develop interstitial pneumonitis (IP), which can be caused by various factors; one of the most important factors is Pneumocystis jirovecii. It is crucial to investigate the pathophysiology of IP and implement preventive measures since IP can be fatal for some people. The data were collected from the First Affiliated Hospital, Zhejiang University School of Medicine, where patients with B-cell lymphoma received the R-CHOP/R-CDOP regimen with or without prophylactic use of trimethoprim-sulfamethoxazole (TMP-SMX). Multivariable logistic regression and propensity score matching (PSM) were used to investigate any potential association. Eight hundred thirty-one patients with B-cell lymphoma were classified into two groups: the non-prophylaxis group without TMP-SMX (n=699) and the prophylaxis group with TMP-SMX (n = 132). IP occurred in 66 patients (9.4%, all in the non-prophylaxis group), with an onset median of three cycles of chemotherapy. Multiple logistic regression analysis demonstrated that IP incidence was associated with pegylated liposome doxorubicin (OR=3.29, 95% CI 1.84-5.90, P<0.001). After utilizing a 1:1 matching algorithm for PSM, 90 patients from each group were obtained. There was a statistical difference between the two cohorts in the IP incidence (non-prophylaxis 12.2% vs prophylaxis 0.0%, P <0.001). The prophylactic use of TMP-SMX could prevent the occurrence of IP whose risk factor was pegylated liposome doxorubicin after chemotherapy for B-cell lymphoma.
MeSH term(s)	Humans ; Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects ; Pneumonia, Pneumocystis/etiology ; Pneumonia, Pneumocystis/prevention & control ; Liposomes ; Propensity Score ; Rituximab/adverse effects ; Vincristine/adverse effects ; Prednisone ; Doxorubicin/adverse effects ; Lung Diseases, Interstitial/chemically induced ; Lung Diseases, Interstitial/prevention & control ; Lung Diseases, Interstitial/complications ; Cyclophosphamide ; Polyethylene Glycols ; Lymphoma, B-Cell/drug therapy ; Lymphoma, B-Cell/complications ; Retrospective Studies
Chemical Substances	Trimethoprim, Sulfamethoxazole Drug Combination (8064-90-2) ; Liposomes ; Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; Prednisone (VB0R961HZT) ; liposomal doxorubicin ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P) ; Polyethylene Glycols (3WJQ0SDW1A)
Language	English
Publishing date	2023-06-06
Publishing country	Germany
Document type	Journal Article
ZDB-ID	1064950-5
ISSN	1432-0584 ; 0939-5555 ; 0945-8077
ISSN (online)	1432-0584
ISSN	0939-5555 ; 0945-8077
DOI	10.1007/s00277-023-05303-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.181: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of

Luo, Shuna / Xu, Xiaofei / Ye, Xingnong / Zhu, Xiaoqiong / Wu, Cai / Chen, Dan / Jin, Jingxia / Zheng, Yan / Zheng, Mengli / Huang, Jian

OncoTargets and therapy

2020 Volume 13, Page(s) 10143–10148

Abstract: Myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U) is a subtype of MDS/MPN that exhibits a combination of the features of both MDS and MPN. To date, no curative treatment is available for MDS/MPN-U; however, previous studies ...

Abstract	Myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U) is a subtype of MDS/MPN that exhibits a combination of the features of both MDS and MPN. To date, no curative treatment is available for MDS/MPN-U; however, previous studies have suggested a potential survival advantage for ruxolitinib and hypomethylating agents. We reported a case of a
Language	English
Publishing date	2020-10-09
Publishing country	New Zealand
Document type	Case Reports
ZDB-ID	2495130-4
ISSN	1178-6930
ISSN	1178-6930
DOI	10.2147/OTT.S272207
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Successful alternative treatment for relapsed adult acute lymphoblastic leukemia with dendritic cells-cytokine-induced killer cells combined with a rituximab-based regimen.

Xiao, XiaoFang / Ye, XingNong / Xu, Cheng / Huang, Jian

OncoTargets and therapy

2018 Volume 11, Page(s) 7555–7558

Abstract: Objective: Acute lymphoblastic leukemia (ALL) is a malignant disease characterized by the accumulation of lymphoblasts, and a poor prognosis for adults with ALL is closely associated with disease recurrence. Thus far, treatment approaches have been ... ...

Abstract	Objective: Acute lymphoblastic leukemia (ALL) is a malignant disease characterized by the accumulation of lymphoblasts, and a poor prognosis for adults with ALL is closely associated with disease recurrence. Thus far, treatment approaches have been limited, particularly in patients who are unable to tolerate chemotherapy. In this study, we report an effective treatment for such patients. Materials and methods: A 52-year-old man diagnosed with Ph-negative B-precursor ALL went into remission after inductive treatment. Unfortunately, when he subsequently relapsed, severe complications drove him to refuse intensive chemotherapy. Instead, he received a cycle of dendritic cells-cytokine-induced killer cells (DC-CIK) before chemotherapy. Result: The patient tolerated rituximab in combination with a vincristine, daunorubicin, l-asparaginase, and prednisone regimen without complications, and was in remission after DC-CIK infusion. After consolidation chemotherapy, including rituximab followed by eight cycles of DC-CIK, the patient has been free of leukemia for 2 years since the relapse. Conclusion: This case of relapsed ALL was successfully treated with DC-CIK combined with a rituximab regimen.
Language	English
Publishing date	2018-10-29
Publishing country	New Zealand
Document type	Case Reports
ZDB-ID	2495130-4
ISSN	1178-6930
ISSN	1178-6930
DOI	10.2147/OTT.S177503
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: PML-RARA monitoring in newly diagnosed acute promyelocytic leukemia treated with an entirely oral chemotherapy-free postremission approach: A multiple institution experience.

Lou, Yinjun / Lu, Ying / Ye, Xingnong / Wang, Yungui / Ma, Yafang / Fan, Cuihua / Jiang, Huifang / Jin, Jie

Hematological oncology

2020 Volume 38, Issue 4, Page(s) 618–621

MeSH term(s)	Administration, Oral ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Arsenicals/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Leukemia, Promyelocytic, Acute/blood ; Leukemia, Promyelocytic, Acute/diagnosis ; Leukemia, Promyelocytic, Acute/drug therapy ; Leukemia, Promyelocytic, Acute/genetics ; Male ; Middle Aged ; Oncogene Proteins, Fusion/blood ; Oncogene Proteins, Fusion/genetics ; Retrospective Studies ; Tretinoin/administration & dosage
Chemical Substances	Arsenicals ; Oncogene Proteins, Fusion ; promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein ; Tretinoin (5688UTC01R)
Language	English
Publishing date	2020-07-29
Publishing country	England
Document type	Clinical Trial ; Letter ; Multicenter Study
ZDB-ID	604884-5
ISSN	1099-1069 ; 0278-0232
ISSN (online)	1099-1069
ISSN	0278-0232
DOI	10.1002/hon.2766
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1816: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With

Ma, Liya / Liang, Bin / Hu, Huixian / Yang, Wenli / Lin, Shengyun / Cao, Lihong / Li, Kongfei / Kuang, Yuemin / Shou, Lihong / Jin, Weimei / Lan, Jianping / Ye, Xingnong / Le, Jing / Lei, Huyi / Fu, Jiaping / Lin, Ying / Jiang, Wenhua / Zheng, Zhiying / Jiang, Songfu /

Fu, Lijuan / Su, Chuanyong / Yin, XiuFeng / Liu, Lixia / Qin, Jiayue / Jin, Jie / Qian, Shenxian / Ouyang, Guifang / Tong, Hongyan

Frontiers in oncology

2022 Volume 12, Page(s) 905490

Abstract: The outcomes of myelodysplastic syndrome (MDS) patients ... ...

Abstract	The outcomes of myelodysplastic syndrome (MDS) patients with
Language	English
Publishing date	2022-06-27
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2022.905490
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito